Table 3.
Details of pharmacotherapy regimens in patients with 6‐month follow‐up data
| Target biomarker | Cancer type | Treatment | n = 212 |
|---|---|---|---|
| Biomarker‐directed regimens | 32 | ||
| ALK | |||
|
CLTC/ALK Fusion CTNNA1/ALK Fusion ITSN2/ALK Fusion EML4/ALK Fusion |
STS Salivary gland carcinoma Bone sarcoma Cholangiocarcinoma |
ALK TKI ALK TKI ALK TKI ALK TKI |
2 1 1 1 |
| BRAF | |||
| BRAF V600E | Nonglial tumor of CNS, STS | BRAF inhibitor + MEK inhibitor | 2 |
| Cell cycle gene | |||
|
CDK4 amplification CCND1 amplification CDKN2A homozygous deletion |
STS Breast carcinoma STS |
CDK4/6 inhibitor CDK4/6 inhibitor CDK4/6 inhibitor + hormone therapy |
1 1 1 |
| FGFR | |||
|
FGFR2/CRIP1 Fusion FGFR2 rearrangement (FISH) |
Skin carcinoma Cholangiocarcinoma |
FGFR inhibitor FGFR inhibitor |
1 1 |
| HER2 | |||
| HER2 amplification | Breast carcinoma | HER2 inhibitor + Capecitabine | 1 |
| HER2 amplification | Breast carcinoma | T‐DM1 | 1 |
| HER2 amplification | Breast carcinoma | HER2 inhibitor | 1 |
| HER3 | |||
| HER3 protein overexpression | Breast carcinoma | HER3 inhibitor | 1 |
| Homologous recombination deficiency (HRD) | |||
|
BRCA1 Q1721X BRCA2 E1299X |
Breast carcinoma Breast carcinoma |
PARP inhibitor PARP inhibitor |
1 1 |
| IDH | |||
| IDH1 R132H | Glial tumor of CNS | IDH inhibitor | 1 |
| KIT | |||
| KIT V559A | Thymus carcinoma | Multi‐TKI | 1 |
| MDM2 | |||
| MDM2 amplification | STS | MDM2 inhibitor | 3 |
| Mismatch repair deficiency | |||
| Loss in either of following four proteins: MLH1/MSH2/MSH6/PMS2 |
Skin carcinoma STS Glial tumor of CNS Uterine cancer |
PD‐1 inhibitor PD‐1 inhibitor PD‐1 inhibitor PD‐1 inhibitor |
1 1 1 1 |
| ROS1 | |||
| GOPC/ROS1 Fusions | Small bowel carcinoma | Selective TKI | 1 |
| ER | |||
| ER protein overexpression | Breast carcinoma | Hormone therapy | 1 |
| PDGFR | |||
| PDGFB rearrangement (FISH) | STS | Multi‐TKI | 2 |
| Other | |||
| (not identified) | Paraganglioma | Pan‐ERBB inhibitor | 1 |
| Non‐biomarker‐directed regimens | 180 | ||
|
1. STS 2. Salivary gland carcinoma, etc. |
PD‐1 inhibitor | 30 | |
|
1. STS 2. Glial tumor of CNS |
Eribulin Mesilate | 21 | |
|
1. Salivary gland carcinoma 2. Nonglial tumors, etc. |
Platinum containing | 18 | |
|
1. STS 2. Breast carcinoma, etc. |
Doxorubicin Hydrochloride containing | 12 | |
| 1. STS | Pazopanib Hydrochloride | 13 | |
| 1. STS | Trabectedin | 10 | |
|
1. Glial tumor of CNS 2. STS |
Temozolomide | 9 | |
|
1. STS 2. Bladder carcinoma, etc. |
Taxane containing | 7 | |
|
1. Salivary gland carcinoma 2. Thymus carcinoma, etc. |
TS‐1 | 6 | |
| 1. Glial tumor of CNS | Bevacizumab | 5 | |
|
1. STS 2. Melanoma of mucosa |
Dacarbazine | 5 | |
| 1. STS | Ifosfamide containing | 5 | |
|
1. STS 2. CUP |
Irinotecan Hydrochloride Hydrate containing | 5 | |
|
1. Bladder carcinoma 2. STS, etc. |
Cell cycle gene inhibitor | 3 | |
|
1. Breast carcinoma 2. Vulva carcinoma, etc. |
Vinca alkaloid containing | 4 | |
| 1. Breast carcinoma | Capecitabine | 3 | |
|
1. Breast carcinoma 2. Bladder carcinoma, etc. |
Gemcitabine Hydrochloride | 3 | |
|
1. Cholangiocarcinoma 2. CUP, etc. |
PD‐L1 inhibitor | 3 | |
|
1. Small bowel carcinoma 2. CUP |
Fluorouracil containing | 2 | |
| 1. STS | Cyclophosphamide Hydrate containing | 2 | |
|
1. GIST 2. CUP |
Multi TKI | 2 | |
| 1. Neuroendocrine tumor | Amrubicin Hydrochloride | 1 | |
| 1. Bladder carcinoma | ATR inihibitor | 1 | |
| 1. Bone sarcoma | Everolimus + Multi TKI | 1 | |
| 1. Nonglial tumor | FGFR inhibitor | 1 | |
| 1. Bladder carcinoma | MDM2 inhibitor | 1 | |
| 1. STS | MET inhibitor | 1 | |
| 1. CUP | mTOR inhibitor | 1 | |
| 1. Neuroendocrine tumor | Octreotide Acetate | 1 | |
| 1. Bladder carcinoma | PARP inhibitor | 1 | |
| 1. Embryonal neoplasm | Regorafenib Hydrate | 1 | |
| 1. STS | Tissue factor inhibitor | 1 | |
| 1. CUP | Trifluridine/Tipiracil Hydrochloride | 1 | |
CNS, central nervous system; CUP, carcinoma of unknown primary; FGFR, fibroblast growth factor receptor; FISH, fluorescent in situ hybridization; GIST, gastrointestinal stromal sarcoma; STS, soft tissue sarcoma; T‐DM1, trastuzumab emtansine; TKI, tyrosine kinase inhibitor.